0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prevalence and clinical features of most frequent phenotypes in the Italian COPD population: the CLIMA Study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Chronic obstructive pulmonary disease (COPD) is a complex, progressive respiratory condition characterized by heterogeneous clinical presentations (phenotypes). The aim of this study was to assess the prevalence of the main COPD phenotypes and match of each phenotype to the most fitting clinical and lung function profile.

          Methods

          the CLIMA (Clinical Phenotypes in Actual Clinical Practice) study was an observational, cross-sectional investigation involving twenty-four sites evenly distributed throughout Italy. Patients were tentatively grouped based on their history and claimed prevailing symptoms at recruitment: chronic cough (CB, suggesting chronic bronchitis); dyspnoea (possible emphysema components, E); recurrent wheezing (presuming asthma components, A). Variables collected were: anagraphics; smoking habit; history of asthma; claim of >1 exacerbations in the previous year; blood eosinophil count; total blood IgE and alpha 1 anti-trypsin (α 1-AT) levels; complete lung function, and the chest X-ray report. mMRC, CAT, BCS, EQ5d-5L were also used. The association between variables and phenotypes were checked by Chi-square test and multinomial logistic regression.

          Results

          The CB phenotype was prevalent (48.3%), followed by the E and the A phenotypes (38.8% and 12.8%, respectively). When dyspnoea was the prevailing symptom, the probability of belonging to the COPD-E phenotype was 3.40 times higher. Recurrent wheezing was mostly related to the COPD-A phenotype. Lung function proved more preserved in the COPD-CB phenotype. Smoke; n. exacerbations/year; VR, and BODE index were positively correlated with the COPD-E phenotype, while SpO 2, FEV 1/FVC, FEV 1/VC, and FEV 1 reversibility were negatively correlated. Lower DLco values were highly probative for the COPD-E phenotype (p<0.001). Conversely, smoke, wheezing, plasma eosinophils, FEV 1 reversibility, and DLco were positively correlated with the COPD-A phenotype. The probability of belonging to the COPD-A phenotype raised by 2.71 times for any increase of one unit in % plasma eosinophils (p<0.001). Also multiparametrical scores contributed to discriminate the three phenotypes.

          Conclusion

          The recognition of the main phenotypes of COPD can be effectively pursued by means of a few clinical and instrumental parameters, easy to obtain also in current daily practice. The phenotypical approach is crucial in the management of COPD as it allows to individualize the therapeutic strategy and to obtain more effective clinical outcomes.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          Susceptibility to exacerbation in chronic obstructive pulmonary disease.

          Although we know that exacerbations are key events in chronic obstructive pulmonary disease (COPD), our understanding of their frequency, determinants, and effects is incomplete. In a large observational cohort, we tested the hypothesis that there is a frequent-exacerbation phenotype of COPD that is independent of disease severity. We analyzed the frequency and associations of exacerbation in 2138 patients enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Exacerbations were defined as events that led a care provider to prescribe antibiotics or corticosteroids (or both) or that led to hospitalization (severe exacerbations). Exacerbation frequency was observed over a period of 3 years. Exacerbations became more frequent (and more severe) as the severity of COPD increased; exacerbation rates in the first year of follow-up were 0.85 per person for patients with stage 2 COPD (with stage defined in accordance with Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages), 1.34 for patients with stage 3, and 2.00 for patients with stage 4. Overall, 22% of patients with stage 2 disease, 33% with stage 3, and 47% with stage 4 had frequent exacerbations (two or more in the first year of follow-up). The single best predictor of exacerbations, across all GOLD stages, was a history of exacerbations. The frequent-exacerbation phenotype appeared to be relatively stable over a period of 3 years and could be predicted on the basis of the patient's recall of previous treated events. In addition to its association with more severe disease and prior exacerbations, the phenotype was independently associated with a history of gastroesophageal reflux or heartburn, poorer quality of life, and elevated white-cell count. Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype. This has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT00292552.)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The natural history of chronic airflow obstruction.

            A prospective epidemiological study of the early stages of the development of chronic obstructive pulmonary disease was performed on London working men. The findings showed that forced expiratory volume in one second (FEV1) falls gradually over a lifetime, but in most non-smokers and many smokers clinically significant airflow obstruction never develops. In susceptible people, however, smoking causes irreversible obstructive changes. If a susceptible smoker stops smoking he will not recover his lung function, but the average further rates of loss of FEV1 will revert to normal. Therefore, severe or fatal obstructive lung disease could be prevented by screening smokers' lung function in early middle age if those with reduced function could be induced to stop smoking. Infective processes and chronic mucus hypersecretion do not cause chronic airflow obstruction to progress more rapidly. There are thus two largely unrelated disease processes, chronic airflow obstruction and the hypersecretory disorder (including infective processes).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The nature of small-airway obstruction in chronic obstructive pulmonary disease.

              Chronic obstructive pulmonary disease (COPD) is a major public health problem associated with long-term exposure to toxic gases and particles. We examined the evolution of the pathological effects of airway obstruction in patients with COPD. The small airways were assessed in surgically resected lung tissue from 159 patients--39 with stage 0 (at risk), 39 with stage 1, 22 with stage 2, 16 with stage 3, and 43 with stage 4 (very severe) COPD, according to the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The progression of COPD was strongly associated with an increase in the volume of tissue in the wall (P<0.001) and the accumulation of inflammatory mucous exudates in the lumen (P<0.001) of the small airways. The percentage of the airways that contained polymorphonuclear neutrophils (P<0.001), macrophages (P<0.001), CD4 cells (P=0.02), CD8 cells (P=0.038), B cells (P<0.001), and lymphoid aggregates containing follicles (P=0.003) and the absolute volume of B cells (P=0.03) and CD8 cells (P=0.02) also increased as COPD progressed. Progression of COPD is associated with the accumulation of inflammatory mucous exudates in the lumen and infiltration of the wall by innate and adaptive inflammatory immune cells that form lymphoid follicles. These changes are coupled to a repair or remodeling process that thickens the walls of these airways. Copyright 2004 Massachusetts Medical Society
                Bookmark

                Author and article information

                Contributors
                Role: on behalf of the CLIMA Study Group
                Journal
                Multidiscip Respir Med
                MRM
                Multidisciplinary Respiratory Medicine
                PAGEPress Publications, Pavia, Italy
                1828-695X
                2049-6958
                01 October 2021
                15 January 2021
                : 16
                : 1
                : 790
                Affiliations
                [1 ]National Center for Respiratory Pharmacoeconomics and Pharmacoepidemiology , Verona
                [2 ] ICS Maugeri IRCCS, Cassano delle Murge (BA)
                [3 ]Institute of Biomedicine and Molecular Immunology , National Research Council, Palermo
                [4 ]Pharmacology Operative Unit, University Hospital Authority “Mater Domini” , Catanzaro
                [5 ]Pneumologia e Fisiopatologia Toraco-Polmonare, Azienda Ospedaliera Universitaria Careggi , Firenze
                [6 ] C.P.M., Giarre (CT)
                [7 ]Occupational Health and Rehabilitation Clinic, ICS Maugeri IRCCS , Pavia
                [8 ]Pneumology Operative Unit, University Hospital Authority , Sassari
                [9 ]Pneumology Rehabilitation Unit, ICS Maugeri IRCCS, Veruno (NO)
                [10 ]Pneumology Rehabilitation Unit, University Hospital Authority , Policlinico Vittorio Emanuele, Catania
                [11 ]Departmental Structure for Territorial Pneumology, Local Health Authority, Matera
                [12 ]Pneumology Clinic, University Hospital Authority , Hospital “G. Rasori”, Parma
                [13 ]Research and Clinical Governance , Verona, Italy
                Author notes
                National Center for Respiratory Pharmacoeconomics and Pharmacoepidemiology, via G. Rossetti 4, 37124 Verona, Italy. robertodalnegro@ 123456gmail.com

                Contributions: RWDN, PT, planned the study and wrote the manuscript; PT, provided critical feedback and contributed to the final version of the manuscript. All other Authors contributed to the patients’ recruitment. All the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

                Conflict of interest: Authors declare no conflict of interest in the present investigation. RWD is Associate Editor of Multidisciplinary Respiratory Medicine.

                Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

                Ethics approval and consent to participate: The study was approved by the Ethical Committee of Perugia during the session of 2017, June 15 th. All subjects gave their informed consent to the anonymous use of their own data for research purposes.

                Consent for publication: All subjects gave their informed consent.

                Article
                10.4081/mrm.2021.790
                8506204
                34733506
                d1318a1a-be28-4cfd-b4d3-fa2638de505f
                ©Copyright: the Author(s)

                This work is licensed under a Creative Commons Attribution NonCommercial 4.0 License (CC BY-NC 4.0).

                History
                : 04 June 2021
                : 16 July 2021
                Page count
                Figures: 2, Tables: 6, Equations: 0, References: 50, Pages: 10
                Categories
                Original Research Article

                Respiratory medicine
                copd,copd phenotypes,clinical pictures,chronic bronchitis,emphysema,bronchial asthma,airway disease

                Comments

                Comment on this article